Navigation Links
Kenrico Announces Records of Patents for 2012 and Financial Targets for 2013
Date:1/22/2013

atent 4485940 – European Patent 03720506.09), was approved by Health Canada in Canada and in Europe by European Medical Device Agency. Separately, the company entered into strategic agreements with pharmaceutical companies to market nattokinase based Lexirin globally to physician for prevention of cell death. Apoptotic cell death plays a significant role in the tissue damage that occurs in association with aging and various abnormal conditions, for example, ischemia and various gastrointestinal disorders.

  •     LEXIRIN ® (US Patent 6,793,945 – 6,413,556), is a medical breakthrough in the treatment of gastrointestinal disorders, deleterious dermatological conditions, immunosuppression or immunodeficiency, reperfusion damage resulting from ischemia, cardiovascular disorders, transplantation, wound healing, tissue rejection and Alzheimer's disease, and the treatment of adverse reactions from medications. LEXIRIN also can significantly decrease conditions and diseases related to aging and blocked blood circulation. LEXIRIN has passed US FDA's Phase I human clinical trials at Alta Bates Medical Center in Berkeley.
  •     ION SHOWER HEAD EX ®, ION WATER PURIFIER ®, FOREVER ALKALINE WATER STICK PURIFIER ®. A technological advancement in water treatment technology that blends natural quartz, citrine crystals and natural minerals from Japanese hot springs for health and stress treatment.
  • Financial targets
    Kenrico continues to expect full year 2013 revenue to double from a base of $149 million in 2012.

    In addition, the company updated its anticipated consolidated tax rate to range of 10 percent.

    About Kenrico
    Kenrico is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1985, Kenrico currently discovers, develops, manufactures and markets prescription and alternative medicines to add
    '/>"/>

    Source: PRWeb
    Copyright©2012 Vocus, Inc.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    6. WuXi PharmaTech Announces Third-Quarter 2011 Results
    7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    8. Spherix Announces Third Quarter Financial Results
    9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
    11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
    (Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
    (Date:10/20/2014)... 20, 2014 Local veterinary surgeon, Dr. ... investigational study of donor stem cells for dogs with ... therapy and has performed clinical stem cell therapy for ... to determine if a single injection of donor stem ... help reduce pain and inflammation in the treated joints. ...
    (Date:10/19/2014)... (PRWEB) October 19, 2014 The ... bromine market in Asia-Pacific with analysis and forecast ... the Asia Pacific Bromine Market report, to get ... also provides a glimpse of the segmentation in ... various tables and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html ...
    Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
    ... with drug-eluting,stents must take a combination of aspirin ... year, and possibly longer, after stent,implantation. This is ... today in the journals of the Society for ... (ACC), and,American Heart Association (AHA). To access the ...
    ... Oral Presentation of the US Oncology Adjuvant Trial ... Symposium Showed Taxotere(R) and Cyclophosphamide ... SAN ANTONIO, Dec. 13 Results presented ... (SABCS) showed that for,women with early stage breast ...
    ... the premier,online community for the medical device ... edition of the US Device(TM) Hotbed,Campaign. DeviceSpace.com ... event, company and other valuable information specific ... The US Device(TM),Hotbed campaign features both a ...
    Cached Biology Technology:PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 2PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 3PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5DeviceSpace.com Launches Marketing Campaign for US Medical Device Industry 2
    (Date:10/18/2014)... genetic conditions, a certain type of exome sequencing method ... traditional molecular diagnostic methods, according to a study appearing ... to coincide with the American Society of Human Genetics ... region of the genome (the complete set of genes ... has been rapidly applied in research settings and recent ...
    (Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
    (Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
    Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
    ... the body regulates blood pressure in response to daily ... helping people whose pressure is out of control. ... pressure is not controlled despite the best efforts of ... director of the Georgia Prevention Institute at the Medical ...
    ... Jabra BT530 First Product to Feature Noise Blackout(TM), ... the world leader in,innovative headset solutions, today unveiled ... Blackout(TM) reduces ambient sound,without compromising voice quality, providing ... of a natural sounding voice. The Jabra,BT530, shipping ...
    ... as a flavor enhancer in their food are more likely than ... though they have the same amount of physical activity and total ... Hill School of Public Health study published this month in the ... studied more than 750 Chinese men and women, aged between 40 ...
    Cached Biology News:Blood pressure response to daily stress provides clues for better hypertension treatment 2Blood pressure response to daily stress provides clues for better hypertension treatment 3Blood pressure response to daily stress provides clues for better hypertension treatment 4Blood pressure response to daily stress provides clues for better hypertension treatment 5Blood pressure response to daily stress provides clues for better hypertension treatment 6GN Netcom Introduces Innovative Noise Blackout Technology 2GN Netcom Introduces Innovative Noise Blackout Technology 3UNC researchers find MSG use linked to obesity 2
    Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
    ... Hamamatsu C9136 FLIM system combines the space and ... the resolution of the optical microscope to open ... short, pulsed light source for excitation, the decay ... the lifetime of the decay measured. Subtle ...
    ...
    SDS-OutT Precipitation Reagent...
    Biology Products: